EBITDA: Income before interest, taxes, depreciation and amortization.
Monte Rosa Therapeutics, Inc. (GLUE) had EBITDA of $-47.22M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$8.97M |
|
$-43.40M |
|
-- |
|
$8.97M |
|
$58.10M |
|
$-49.13M |
|
$5.94M |
|
$-43.19M |
|
$-43.19M |
|
$-43.40M |
|
$-43.40M |
|
$-43.40M |
|
$-43.40M |
|
$-49.13M |
|
|
EBITDA |
$-47.22M |
101.48M |
|
101.48M |
|
$-0.43 |
|
$-0.43 |
|
| Balance Sheet Financials | |
$631.41M |
|
$29.93M |
|
$59.76M |
|
$691.16M |
|
$59.66M |
|
-- |
|
$144.22M |
|
$203.88M |
|
$487.28M |
|
$487.28M |
|
$487.28M |
|
85.23M |
|
| Cash Flow Statement Financials | |
$-81.48M |
|
$-289.86M |
|
$331.55M |
|
$134.84M |
|
$95.04M |
|
$-39.79M |
|
$11.92M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-547.84% |
|
-547.84% |
|
-- |
|
-481.59% |
|
-483.91% |
|
$-88.07M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
1.82 |
|
49.38 |
|
-8.91% |
|
-8.91% |
|
-6.28% |
|
-8.91% |
|
$5.72 |
|
$-0.87 |
|
$-0.80 |
|